Clinical trials: Cytomegalovirus Prophylaxis
CMV Infection, Hematopoietic Stem Cell Transplantation
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
- Trial name
- NCT06021210
- Testing
- Letermovir Pill
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Cytomegalovirus Infections, HIV Infections
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
To evaluate the efficacy of oral ganciclovir in preventing progression to cytomegalovirus (CMV) disease (e.g., CMV retinitis, gastrointestinal CMV disease) in CMV-infected people with HIV infection and CD4 lymphocyte counts <=…
- Trial name
- NCT00002095
- Testing
- Ganciclovir
- Where
- 19 sites in United States
- Volunteers
- 700 people
- Sponsor
- Hoffmann-La Roche
CMV, CMV Infection
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
The purpose of this study is to determine of letermovir (LTC) is effective at preventing Cytomegalovirus (CMV) infection from returning in people who have already had CMV infection after a bone marrow transplant.
- Conditions
- CMV, CMV Infection, Hematopoietic Cell Transplant
- Trial name
- NCT04017962
- Testing
- Letermovir Pill, blood draw
- Where
- 2 sites in United States
- Volunteers
- 102 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epstein-Barr Virus Infections, Adenovirus
Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV
This protocol is a phase I study. Patients may be eligible for an infusion of Multi-virus Cytotoxic T Lymphocytes (CTL) if they received a T-cell depleted (TCD) transplant from a related family member or an unrelated donor.
- Conditions
- Epstein-Barr Virus Infections, Adenovirus, Cytomegalovirus Infections
- Trial name
- ACE (NCT01535885)
- Testing
- Cytotoxic T Lymphocytes
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Medical College of Wisconsin
Viral Infection
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
The subjects eligible for this trial have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- ARMS (NCT01570283)
- Testing
- Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- AlloVir
Blood Transfusion, Cytomegalovirus Infections
Transfusion-Transmitted Cytomegalovirus Prevention in Neonates
To evaluate the capacity of intravenously administered cytomegalovirus (CMV)-immune globin (CMVIG) to immunize high risk premature infants against CMV infections.
- Trial name
- NCT00000584
- Testing
- immunoglobulins
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cytomegalovirus Prophylaxis
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds).
- Trial name
- NCT07199465
- Testing
- Letermovir
- Where
- 22 sites in United States
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
Immunoglobulin Prophylaxis, Cytomegalovirus Infections
Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Human cytomegalovirus (CMV) is a globally prevalent, human-specific herpesvirus characterised by a lifelong latency after primary infection, an often asymptomatic reactivation and affecting up to 100% of adults based on region…
- Conditions
- Immunoglobulin Prophylaxis, Cytomegalovirus Infections, Allogeneic Hematopoietic Stem Cell Transplantation, Transplant-Related Disorder
- Trial name
- NCT07013370
- Testing
- Anti-CMV immunoglobulins [Megalotect (R)]
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Antonello Di Paolo, M.D., Ph.D.
Cytomegalovirus Congenital
Primary Prevention of Cytomegalovirus in Pregnancy: Addressing the Gaps (CMV GAP)
CMV is the most common congenital infection (an infection acquired before birth) in the UK. It is the leading non-genetic cause of sensorineural (inner ear) hearing loss and a common cause of neuro-disability.
- Trial name
- CMV GAP (NCT04879784)
- Testing
- No intervention
- Volunteers
- 6,000 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Cytomegalovirus Infections
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
This study will determine the relative efficacy and safety of up to 100 days Valcyte prophylaxis relative to up to 200 days Valcyte prophylaxis when given for the prevention of CMV disease in high-risk (D+/R-) kidney allograft…
- Trial name
- IMPACT (NCT00294515)
- Testing
- Valganciclovir
- Where
- 80 sites in United States, Australia and 11 more
- Volunteers
- 326 people
- Sponsor
- Hoffmann-La Roche
Transplantation Infection, Epstein-Barr Virus Infections
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Our study will compare all kidney transplant recipients receiving valganciclovir vs. valacyclovir for one year following kidney transplant and compare: 1.
- Conditions
- Transplantation Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections
- Trial name
- NCT01972035
- Testing
- Valacyclovir, Valganciclovir
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University of Minnesota
Cytomegalovirus Infection Reactivation
Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation
- Trial name
- NCT06441669
- Testing
- Letermovir
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Cytomegalovirus Retinitis, HIV Infections
The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV
To evaluate the safety and efficacy of oral ganciclovir for prophylaxis against cytomegalovirus (CMV) retinal and gastrointestinal mucosal disease in HIV-infected patients with severe immunosuppression.
- Conditions
- Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
- Trial name
- NCT00001034
- Testing
- Ganciclovir
- Where
- 17 sites in United States
- Volunteers
- 850 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections
Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant
Patients have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- VICTA (NCT00078533)
- Testing
- CMV CTL infusion
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Baylor College of Medicine
Cytomegalovirus Infections, HIV Infections
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
PRIMARY: To evaluate the efficacy of valacyclovir hydrochloride (BW 256U87) in the prevention of cytomegalovirus (CMV) end-organ disease in HIV/CMV co-infected patients with CD4+ lymphocytes < 100 cells/mm3.
- Trial name
- NCT00001038
- Testing
- Valacyclovir hydrochloride, Acyclovir
- Where
- 35 sites in United States, Australia and 8 more
- Volunteers
- 1,200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adenovirus Infection, BK Virus Infection
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT04693637)
- Testing
- Posoleucel (ALVR105)
- Where
- 16 sites in United States
- Volunteers
- 26 people
- Sponsor
- AlloVir
The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
To evaluate the efficacy and safety of primary prophylaxis of CMV reactivation, clinically significant CMV infection with oral letermovir in Chinese R+ haplo-HSCT patients, as well as treatment-related mortality and all-cause…
- Trial name
- NCT05914675
- Testing
- Letermovir
- Volunteers
- 21 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China